GlassScriptPhysician profile
Brianna Mcdaniel
NPI 1285053496
$2,624.56
in general payments reported to CMS, 2019-2025
26 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $120 · 2021: $696 · 2022: $648 · 2023: $257 · 2024: $320 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.72 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $482.70 | 2019-2025 | |
| Allergan, INC. | $267.81 | 2021-2022 | |
| Genzyme Corporation | $266.77 | 2019-2025 | |
| Janssen Biotech, INC. | $233.18 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $176.02 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $130.18 | 2021-2024 | |
| Galderma Laboratories, L.P. | $119.88 | 2019-2024 | Aklief |
| Janssen Scientific Affairs, LLC | $114.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $97.52 | 2023-2025 | Sotyktu |
| Ucb, INC. | $87.68 | 2019-2024 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $81.63 | 2019-2023 | Dupixent |
| Sun Pharmaceutical Industries INC. | $79.39 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.32 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Pfizer INC. | $65.47 | 2021-2022 | |
| Leo Pharma INC. | $51.43 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $48.06 | 2019-2025 | Klisyri |
| Revance Therapeutics, INC. | $39.28 | 2024 | Daxxify |
| Incyte Corporation | $33.08 | 2021-2022 | |
| Dermavant Sciences, INC. | $29.73 | 2023 | Vtama |
| Lilly USA, LLC | $24.48 | 2022 | |
| Journey Medical Corporation | $24.14 | 2023 | |
| Celgene Corporation | $21.38 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $20.35 | 2022 | |
| Kerecis Limited | $19.67 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Vyne Pharmaceuticals INC. | $18.66 | 2021 | |
| Organogenesis INC. | $17.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.